![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
T Yokota, K Konno, S Mori, S Shigeta, M Kumagai, Y Watanabe and H Machida
Department of Bacteriology, Fukushima Medical College, Japan.
To investigate the mechanism of action of 1-beta-D-arabinofuranosyl-(E)- 5-(2-bromovinyl)uracil (BV-araU) on varicella zoster virus (VZV) replication, we examined the metabolism of the drug in VZV-infected cells using 14C-labeled BV-araU. [14C]BV-araU was taken up by the cells infected with thymidine kinase-positive (TK+)VZV, but not so much by TK- VZV-infected or mock infected cells. Most of the radioactivity in TK+ VZV-infected cells that were incubated with [14C]BV-araU was recovered from their acid-soluble fraction, and little from their acid-insoluble fraction. By high performance liquid chromatographic assay of the acid- soluble fraction, it was proved that BV-araU was metabolized to its 5'- monophosphate, diphosphate, and triphosphate only in TK+ VZV-infected cells. The radioactivity was not detected in VZV nucleocapsids or in VZV DNA and cellular DNA isolated from TK+ VZV-infected cells, even if BV-araU was added at a 1000 times higher concentration than the 50% inhibitory dose for VZV replication in vitro. Furthermore, it was enzymatically proved that [14C]BV-araU was selectively and effectively phosphorylated to BV-araU monophosphate by VZV TK and that affinity of BV-araU triphosphate for VZV DNA polymerase was the quite strong. From these results, it can be concluded that marked inhibition of VZV replication by BV-araU is due to selective phosphorylation of BV-araU in the TK+ VZV-infected cells and strong inhibition of VZV DNA synthesis by BV-araU triphosphate, without detectable incorporation into VZV DNA.
This article has been cited by other articles:
|
|
 |
|
  L. E. Bird, J. Ren, A. Wright, K. D. Leslie, B. Degreve, J. Balzarini, and D. K. Stammers Crystal Structure of Varicella Zoster Virus Thymidine Kinase J. Biol. Chem., June 27, 2003; 278(27): 24680 - 24687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Li, G. E. Dutschman, E. A. Gullen, E. Tsujii, S. P. Grill, Y. Choi, C. K. Chu, and Y.-c. Cheng Metabolism and Mode of Inhibition of Varicella-Zoster Virus by L-beta -5-Bromovinyl-(2-hydroxymethyl)-(1,3-dioxolanyl)uracil Is Dependent on Viral Thymidine Kinase Mol. Pharmacol., November 1, 2000; 58(5): 1109 - 1114. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. W. Gnann Jr., C. S. Crumpacker, J. P. Lalezari, J. A. Smith, S. K. Tyring, K. F. Baum, M. J. Borucki, W. P. Joseph, G. J. Mertz, R. T. Steigbigel, et al. Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial Antimicrob. Agents Chemother., May 1, 1998; 42(5): 1139 - 1145. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
